Generate QR code
Open Access
Subscription Access
CAR-T therapy: today and tomorrow
Abstract
The article analyzes the potential of CAR-T therapy – a genetically engineered cell method that has become a breakthrough in cancer treatment, and highlights the achievements of Belarusian scientists in this cutting-edge field.
About the Authors
Tatyana Doroshenko
РНПЦ онкологии и медицинской радиологии им. Н.Н. Александрова
Belarus
Belarus
Dmitry Dormeshkin
Институт биоорганической химии НАН Беларуси
Belarus
Belarus
Sergey Krasny
РНПЦ онкологии и медицинской радиологии им. Н.Н. Александрова
Belarus
Belarus
References
1. CAR-T cell therapy for cancer: current challenges and future directions / I. Zugasti, L. Espinosa-Aroca, K. Fidyt // Signal Transduct Target Ther. 2025. Jul №4 10(1) Р. 210. https://doi.org/10.1038/s41392-025-02269-w/.
2. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived c regions / Y. Kuwana, Y. Asakura, N. Utsunomiya [et al.] // Biochem Biophys Res C o m m u n . 19 87. №149. Р. 9 6 0 – 9 6 8 . https://doi.org/10.1016/0006-291X(87)90502-X.
3. Gross G. Expression of immunoglobulin-t-cell receptor chimeric molecules as functional receptors with antibody-type specificity / G. Gross, T. Waks, Z. Eshhar // Proc Natl Acad Sci U.S.A. 1989. №86. Р. 10024–10028. https://doi.org/10.1073/pnas.86.24.10024.
4. From bench to bedside: the history and progress of CAR T cell therapy / A. Mitra, A. Barua, L. Huang [et al.] // Front Immunol. 2023. №15. Р. 1188049. https://doi.org/10.3389/fimmu.2023.1188049.
5. T Current updates on generations, approvals, and clinical trials of CAR T-cell therapy / Asmamaw Dejenie, G. Tiruneh M. Medhin [et al.] // Hum Vaccin Immunother. 2022. №18(6). Р. 2114254. https://doi.org/10.1080/21645515.2022.2114254.
6. CAR-T cell manufacturing: Major process parameters and next-generation strategies / M. Ayala Ceja, M. Khericha, C. M. Harris [et al.] // J Exp Med. 2024. №221(2). Р. e20230903. https://doi.org/10.1084/jem.20230903.
7. Sterner R.C. CAR-T cell therapy: current limitations and potential strategies / R. C Sterner, R. M. Sterner // Blood Cancer J. 2021. №11(4). Р. 69. https://doi.org/10.1038/s41408-021-00459-7.
8. Alsaieedi A.A. Tracing the development of CAR-T cell design: from concept to next-generation platforms / A.A. Alsaieedi, K.A. Zaher // Front. Immunol. 2025. №16. Р. 1615212. https://doi.org/10.3389/fimmu.2025.1615212.
9. The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies / E.R. Pennings, F.W. Thielen, F. Broussais [et al.] // Hemasphere. 2026. №10(3). Р. e70306. https://doi.org/10.1002/hem3.70306.
10. Hill J.A. CAR-T – and a side order of IgG, to go? Immunoglobulin replacement in patients receiving CAR-T cell therapy / J.A. Hill, S. Giralt, T.R. Torgerson, H.M. Lazarus // Blood Rev. 2019. №38. Р. 100596. https://doi.org/10.1016/j.blre.2019.100596.
11. Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma / X. Deschênes-Simard, M. Bromberg, S.M. Devlin [et al.] // Blood Adv. 2025. №9 (21). Р. 5571–5584.
12. Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies / Y. Zhao, D. Zhang, Y. Guo [et al.] // Front. Oncol. 2021. №11. Р. 680834. https://doi.org/10.3389/fonc.2021.680834.
13. Rebagay G. ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy / G. Rebagay, S. Yan, C. Liu and N.K. Cheung // Front. Oncol. 2012. №2. Р. 34. https://doi.org/10.3389/fonc.2012.00034.
14. Therapeutic advances in the targeting of ROR1 in hematological cancers / A.B. Tigu, R. Munteanu, C. Moldovan [et al.] // Cell Death Discov. 2024. №10(1). Р. 471. https://doi.org/10.1038/s41420-024-02239-1.
15. Lin W. IGFBP5 is an ROR1 ligand promoting glioblastoma invasion via ROR1/HER2-CREB signaling axis / W. Lin, R. Niu, S.M. Park [et al.] // Nat Commun. 2023. №14(1). Р. 1578. https://doi.org/10.1038/s41467-023-37306-1 .
16. Zhu H. ROR1 facilitates glioblastoma growth via stabilizing GRB2 to promote c-Fos expression in glioma stem cells / H. Zhu, L. Cheng, D. Liu [et al.] // Neuro Oncol. 2025. № 27(3). Р. 695–710. https://doi.org/10.1093/neuonc/noae224.
17. Jung M.S. The Role of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Cancer Stem Cell Signaling / M.S. Jung, W.Y. Choi, W. Zhang [et al.] // Int J Mol Sci. 2025. №26(16). Р. 7828. https://doi.org/10.3390/ijms2667828 . PMID : 40869147; PMCID : PMC12386924.
18. Faust J.R. Mesothelin: An Immunotherapeutic Target beyond Solid Tumors / J.R Faust., D. Hamill, E.A. Kolb [et al.] // Cancers. 2022. №14. Р. 1550. https://doi.org/10.3390/cancers14061550.
19. Boisgard R. Mesothelin biology and the evolving landscape of targeted immunotherapy / R. Boisgard, P. Chames, B. Kerfelec //Molecular Therapy Oncology. 2026. №34. Р. 1–6
Review
For citations:
Doroshenko T., Dormeshkin D., Krasny S. CAR-T therapy: today and tomorrow. Science and Innovations. 2026;(6):28-33. (In Russ.)
Views:
67
JATS XML
Email this article 